Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2002
02/14/2002WO2002012325A2 Suppressor gene
02/14/2002WO2002012324A1 A new polypeptide-human l1 factor orf2 reverse transcription-related protein 13 and the polynucleotide encoding it
02/14/2002WO2002012323A1 A new polypeptide- hlyd protein family secretory protein 11 and the polynucleotide encoding it
02/14/2002WO2002012322A1 A new polypeptide-human fk506 binding protein 12.32 and the polynucleotide encoding it
02/14/2002WO2002012321A1 A novel peptide--human nrd transforming enzyme 10.01 and the polynucleotide coding this novel peptide
02/14/2002WO2002012320A1 A novel peptide---human tnfr/ngfr protein including cytochrome c domain and the polynucleotide coding this novel peptide
02/14/2002WO2002012319A1 A NOVEL PEPTIDE---HUMAN Na-K PUMP 14.85 AND THE POLYNUCLEOTIDE CODING THIS NOVEL PEPTIDE
02/14/2002WO2002012318A1 A novel peptide--glycophosphatidylinositol f11.22 and the polynucleotide coding this novel peptide
02/14/2002WO2002012317A1 A novel peptide---estrogen receptor associated protein 19.03 and the polynucleotide coding this novel peptide
02/14/2002WO2002012315A1 A novel polypeptide - ring finger gene mid1 protein 10.56 and a polnucleotide encoding the same
02/14/2002WO2002012313A1 A novel polypeptide - human protein phosphatase 12.43 and a polynucleotide encoding the same
02/14/2002WO2002012311A1 A novel polypeptide - human fasciculation and elongation protein 16.61 and a polynucleotide encoding the same
02/14/2002WO2002012309A1 A new polypeptide- phytochrome 9.9 and the polynucleotide encoding it
02/14/2002WO2002012308A1 A new polypeptide-human rs3 protein 18 and the polynucleotide encoding it
02/14/2002WO2002012307A1 Urocortin proteins and uses thereof
02/14/2002WO2002012306A1 A novel polypeptide-the human non-integrin metalloprotease 10.67 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012305A1 A novel-polypeptide-the avidin 9 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012304A1 A novel polypeptide-mouse transient receptor potential protein 2 (trp2)12 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012303A1 A novel polypeptide-human ribonucleoside dephosphate reductase inhibitor 10.23 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012302A1 A novel polypeptide-the human splicing factor 9.24 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012301A1 A novel polypeptide-insulin-like growth factor binding protein 16.17 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012300A1 A novel polypeptide-human cyclin g29.13 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012299A1 A novel polypeptide-human protein kinase 27.17 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012298A1 A novel polypeptide --the human nadh dehydrogenase subunit i-9 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012297A1 A novel polypeptide- human tropodulin 9 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012296A1 A novel polypeptide-nadp dependent leukotriene b412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide
02/14/2002WO2002012290A2 Sid polypeptides binding to pathogenic strain of the hepatitis c virus
02/14/2002WO2002012287A1 Purification of hbv antigens for use in vaccines
02/14/2002WO2002012286A2 Stress proteins and peptides and methods of use thereof
02/14/2002WO2002012285A2 The tumor suppressor car-1
02/14/2002WO2002012283A2 Disintegrin homologs, zsnk10, zsnk11, and zsnk12
02/14/2002WO2002012282A2 Novel ebi-3-alt protein and nucleic acid molecules and uses therefor
02/14/2002WO2002012281A2 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
02/14/2002WO2002012280A2 Compositions and methods for the therapy and diagnosis of colon cancer
02/14/2002WO2002012276A2 Pleckstrin homology polypeptides and dna encoding such
02/14/2002WO2002012275A2 Lat peptides and their use in assays for identifying immunosuppressants
02/14/2002WO2002012272A2 Therapeutic anti-melanoma compounds
02/14/2002WO2002012271A2 Treatment of microbial infections with bacterial proteins and peptides
02/14/2002WO2002012269A2 Pharmaceutical composition comprising an analgesic peptide
02/14/2002WO2002012196A2 Lactam compounds and their use as inhibitors of serine proteases and method
02/14/2002WO2002012188A2 Indole compounds useful for the treatment of cancer
02/14/2002WO2002011803A1 Electro-powder
02/14/2002WO2002011785A2 Manipulation of arterial-venous identity
02/14/2002WO2002011770A1 Compositions for preventing urinary calculus
02/14/2002WO2002011769A1 Vascular endothelial growth factor 2
02/14/2002WO2002011767A2 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
02/14/2002WO2002011763A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
02/14/2002WO2002011762A2 Methods and compositions for modulating tumor growth
02/14/2002WO2002011755A1 Method
02/14/2002WO2002011754A1 Treatment of hepatitis c with thymosin and pegylated interferon
02/14/2002WO2002011753A1 Protein injection preparations
02/14/2002WO2002011751A2 Combinations of dalfopristine/quinupristine with cefpirome
02/14/2002WO2002011750A2 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
02/14/2002WO2002011749A1 Treatment of hepatitis c with thymosin, interferon and ribavirin
02/14/2002WO2002011748A1 Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
02/14/2002WO2002011747A2 Transglutaminase for inhibiting angiogenesis
02/14/2002WO2002011743A2 Treatment of prostate cancer
02/14/2002WO2002011742A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
02/14/2002WO2002011739A1 Methods for preventing pressure induced apoptotic neural cell death
02/14/2002WO2002011717A1 Cosmetics to support skin metabolism
02/14/2002WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
02/14/2002WO2002011695A2 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
02/14/2002WO2002011677A2 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
02/14/2002WO2002011674A2 Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
02/14/2002WO2002011673A2 Methods of modulating activity of dxr
02/14/2002WO2002011669A2 Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
02/14/2002WO2002011667A2 Pharmaceutical compositions and methods useful for modulating angiogenesis
02/14/2002WO2002011666A2 Derivatives of branched-chain lipophilic molecules and uses thereof
02/14/2002WO2002011511A1 A novel polypeptide-the activating gtpase negative regulator 11.66 and the polynucleotide encoding said polypeptide
02/14/2002WO2002005844A8 Protein complex serving as a vehicle for orally administerable medicaments
02/14/2002WO2001098471A8 Human phosphodiesterases
02/14/2002WO2001092302A8 Human cyslt2 nucleic acids, polypeptides, and uses thereof
02/14/2002WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists
02/14/2002WO2001073018A3 Human tap-like protein (transporter associated in antigen processing/presentation)
02/14/2002WO2001072328A3 Methods of treating diseases with activated protein c
02/14/2002WO2001070766A3 Therapeutic anti-cytomegalovirus compounds
02/14/2002WO2001068670A3 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof
02/14/2002WO2001064874A3 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis
02/14/2002WO2001059120A3 Il-17 like molecules and uses thereof
02/14/2002WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels
02/14/2002WO2001058933A3 Selective n-acylation of a82846 glycopeptide analogs
02/14/2002WO2001058922A3 Method and compositions for treating hepatocellular cancer
02/14/2002WO2001058921A3 Methods and compositions for generating angiostatin
02/14/2002WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10
02/14/2002WO2001058474A3 Microencapsulation and sustained release of biologically active agent
02/14/2002WO2001057210A3 Use of dendroaspin as a vehicle for non-dendroaspin domains
02/14/2002WO2001057187A3 Novel bone marrow nucleic acids and polypeptides
02/14/2002WO2001055302A3 Nucleic acids, proteins, and antibodies
02/14/2002WO2001049705A3 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
02/14/2002WO2001049274A3 Methods for pulmonary delivery of interleukin-2
02/14/2002WO2001048161A3 Human heparanase-related polypeptide and nucleic acid
02/14/2002WO2001047957A3 Human fgf-10- (kgf-2)-like protein zfgf-10
02/14/2002WO2001044502A3 Genetic variants of the human fsh receptor and the influence thereof on gametogenesis
02/14/2002WO2001044446A3 Further human alcohol dehydrogenases
02/14/2002WO2001042464A3 Human preoptic regulatory factor-2 and uses thereof
02/14/2002WO2001042288A3 G-protein coupled receptors
02/14/2002WO2001037852A3 Methods of inhibiting atrophy or promoting hypertrophy
02/14/2002WO2001034641A3 Antimicrobial activity of the first cationic cluster of human lactoferrin
02/14/2002WO2001034088A3 Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders
02/14/2002WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF